logo-alx-oncology-apr18-color.jpg
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
January 05, 2023 07:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
December 12, 2022 10:00 ET | ALX Oncology
-- Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML-- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Appoints Scott Garland to its Board of Directors
November 29, 2022 07:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
November 08, 2022 16:01 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
November 03, 2022 09:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Announces Upcoming Investor Conference Participation
November 02, 2022 07:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
October 31, 2022 07:00 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:01 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
logo-alx-oncology-apr18-color.jpg
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
September 21, 2022 16:01 ET | ALX Oncology
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...